PETACH TIKVA, Israel--(BUSINESS WIRE)--July 20, 2006--Can-Fite BioPharma (TASE:CFBI): Can-Fite BioPharma (TASE:CFBI) has initiated Phase IIb in rheumatoid arthritis patients with its lead drug CF101. At the same time, Can-Fite reports that it has received the final report summarizing the results of the Phase IIa clinical trial in the same patient population showing impressive drug activity. The results appearing in the final report are consistent with the interim results of this study, previously published by the Company.
